ArticleBMC pulmonary medicine2018
Annexin A1 in plasma from patients with bronchial asthma: its association with lung function.
Article in BMC pulmonary medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- A meta-analysis of genome-wide association studies of childhood wheezing phenotypes identifieseLife · 2023Pooled it
- Importance of STAT3 signaling in preeclampsia (Review).International journal of molecular medicine · 2025Review
- Single-cell RNA sequencing unraveled immune-related expression heterogeneity and lymphoid cell development dysregulation in childhood asthma.Frontiers in immunology · 2025Article
- Angiogenesis Factors as Emerging Circulating Biomarkers in Asthma.Allergy, asthma & immunology research · 2025Review
- Exploring Inflammatory Asthma Phenotypes: Proteomic Signatures in Serum and Induced Sputum.International journal of molecular sciences · 2024Article
- The Potential Role of Serum and Exhaled Breath Condensate miRNAs in Diagnosis and Predicting Exacerbations in Pediatric Asthma.Biomedicines · 2023Review
- Olfactomedin 4 as a circulating biomarker for asthma.Annals of translational medicine · 2022Article
- Current Insights on the Impact of Proteomics in Respiratory Allergies.International journal of molecular sciences · 2022Review
- Annexin-A1-Derived Peptide Ac2-26 Suppresses Allergic Airway Inflammation and Remodelling in Mice.Cells · 2022Article
- Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy.Kidney international · 2021Article
- Hemopexin: A Novel Anti-inflammatory Marker for Distinguishing COPD From Asthma.Allergy, asthma & immunology research · 2021Article
- Epigenetic programming underpins B-cell dysfunction in peanut and multi-food allergy.Clinical & translational immunology · 2021Article
- Serum Calprotectin Is a Potential Marker in Patients with Asthma.Journal of Korean medical science · 2020Article
- Formyl peptide receptors in the mucosal immune system.Experimental & molecular medicine · 2020Review
- Reduced Annexin A3 in schizophrenia.European archives of psychiatry and clinical neuroscience · 2020Article
- Hub Genes Identification in a Murine Model of Allergic Rhinitis Based on Bioinformatics Analysis.Frontiers in genetics · 2020Article
- The annexin A1/FPR2 signaling axis expands alveolar macrophages, limits viral replication, and attenuates pathogenesis in the murine influenza A virus infection model.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease.Frontiers in immunology · 2019Review
- Silencing of Annexin A1 suppressed the apoptosis and inflammatory response of preeclampsia rat trophoblasts.International journal of molecular medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAnnexin-A1 (ANXA1) is a glucocorticoid-induced protein with multiple actions in the regulation of inflammatory cell activation. The anti-inflammatory protein ANXA1 and its N-formyl peptide receptor 2 (FPR2) have protective effects on organ fibrosis. However, the exact role of ANXA1 in asthma remains to be determined. The aim of this study was to identify the role of ANXA1 in bronchial asthma.
methodsIn mice sensitized and challenged with ovalbumin (OVA-OVA mice) and mice sensitized with saline and challenged with air (control mice), we investigated the potential links between ANXA1 levels and bronchial asthma using ELISA, immunoblotting, and immunohistochemical staining. Moreover, we also determined ANXA1 levels in blood from 50 asthmatic patients (stable and exacerbated states).
resultsANXA1 protein levels in lung tissue and bronchoalveolar lavage fluid were significantly higher in OVA-OVA mice compared with control mice. FPR2 protein levels in lung tissue were significantly higher in OVA-OVA mice compared with control mice. Plasma ANXA1 levels were increased in asthmatic patients compared with healthy controls. Plasma ANXA1 levels were significantly lower in exacerbated patients compared with stable patients with bronchial asthma (p < 0.05). The plasma ANXA1 levels in controlled asthmatic patients were correlated with forced expiratory volume in 1 s (FEV
conclusionThese results suggest that ANXA1 may be a potential marker and therapeutic target for asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.